The vast majority of non-Hodgkin's lymphomas are of B-cell phenotype. Development of unlabeled or radiolabeled therapeutic monoclonal antibodies against the cell surface antigen, CD20, has revolutionized the treatment of these malignancies. It is clear that antibodies targeting other B-cell-specific molecules, such as CD22, also offer potential therapeutic benefit. Epratuzumab is a humanized anti-CD22 monoclonal, which has undergone preclinical and phase I/II clinical evaluation in patients with indolent or aggressive lymphoma. Data suggest that this agent is well tolerated, and can induce tumor regressions. Trials are currently evaluating its safety and activity in combination with rituximab (chimeric anti-CD20) and standard chemotherapy are ongoing. Initial results suggest that these regimens have acceptable toxicity, and that epratuzumab warrants further evaluation as an adjunct to standard lymphoma treatment regimens.
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Indolent lymphoma (such as FL grades 1 and 2) accounts for approximately one-third of NHL patients. Response rates to most therapies are in the 70-90% range; however, relapses generally occur within a few years and the disease tends to become more resistant to treatment with each successive relapse over time (Gallagher et al., 1986; Winter et al., 2004; Zinzani, 2005) . Both prognosis and therapy are related to the stage of the disease at initial diagnosis. Relatively few patients with early-stage disease are treated with external beam radiotherapy, and can expect to enjoy a significant long-term disease-free survival. However, most patients have advanced-stage disease at diagnosis, and historically options have included careful observation ('watch and wait') as well as alkylating agents and purine analogues as single-agents or in combination (Gallagher et al., 1986; Hiddemann et al., 2005; Zinzani, 2005) . Median survival has been previously reported to be in the range of 8-10 years (Gallagher et al., 1986; Hiddemann et al., 2005) . Other treatment modalities have been explored, including high-dose chemotherapy and autologous stem cell transplantation (AuSCT), and more recently both unlabeled and radiolabeled monoclonal antibodies directed against CD20 have become part of standard regimens (Hiddemann et al., 2005) .
Anti-CD20 therapy with rituximab Rituximab, a chimeric anti-CD20 monoclonal antibody (MAb), has been demonstrated to induce responses (mostly partial) in approximately 50% of previously treated patients and 67% of chemotherapy-naı¨ve patients (McLaughlin et al., 1998; Ghielmini et al., 2004) . Adding rituximab to combination chemotherapy increases the response rate and response duration compared to chemotherapy alone in FL . Retreatment of indolent NHL patients who respond to a course of rituximab single agent therapy for at least 6 months and then progress can result in a second objective response of about 40% of the time (Davis et al., 2000) . This observation has led to the development of extended induction or maintenance regimens, designed to provide additional rituximab doses while the patient is in response after an initial induction regimen, in order to potentially extend remission and improve longer-term outcomes (Ghielmini et al., 2004; Hainsworth, 2004) .
Although rituximab was initially developed for the treatment of indolent lymphoma, perhaps its most important application has been in the treatment of patients with DLBCL, the most common of NHL subtypes accounting for one-third of patients . The natural history of aggressive lymphoma is one of rapidly progressive disease. However, over the last several decades, combination chemotherapy has resulted in cure for at least 40% of patients Coiffier, 2005) . For those patients with primaryrefractory disease, or with relapsed disease after an initial remission, second-line regimens are applied and in a significant number of cases can result in cure either alone or following consolidation with high-dose regimens and AuSCT. Ongoing challenges include those patients who do not respond to primary or secondary therapy, those who relapse after AuSCT, and those who are not candidates for these approaches due to comorbid illness. In selected patients with DLBCL, responses to single-agent rituximab were demonstrated in approximately 30%, but generally were brief in duration (Coiffier et al., 1998) . This led to the addition of rituximab to the standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) regimen Coiffier, 2005) . Randomized trials subsequently showed that the rituximab-CHOP regimen improved event-free and overall survival compared to CHOP alone in patients over 60 years of age with advanced DLBCL (Coiffier et al., 2002) . This and other follow-up studies led to the adoption of rituximab-CHOP as the standard initial treatment for DLBCL in virtually all patients.
Rituximab is a chimeric immunoglobin G 1 (IgG 1 ) MAb directed against the CD20 antigen that is ubiquitous on normal and malignant B cells (Grillo-Lopez, 2000) . The mechanisms responsible for its activity are under intense study and debate, with antibody-dependent cellular cytotoxicity (ADCC), complement-mediated cytotoxicity and direct induction of apoptosis all implicated (Golay et al., 2000; Harjunpaa et al., 2000; Maloney et al., 2002; Johnson and Glennie, 2003) . Although it was initially approved as a monotherapy, it is clear that it can enhance the antitumor effects of chemotherapy (Chow et al., 2002; Jazirehi et al., 2005) or radiation (Skvortsova et al., 2005) . Virtually all indolent and aggressive B-cell NHL patients receive rituximab as part of their initial therapy, as well as at relapse. Despite its important effects, however, further improvements in treatment, including other antibody-based strategies are needed to further improve outcomes or to be used when patients are treatment-refractory.
Radiolabeled and second-generation unlabeled antibodies targeting CD20 One strategy to potentially improve upon the activity of rituximab is to develop other CD20 antibodies engineered to enhance mechanisms of action and overcome pathways of resistance (Leonard, 2005) . Several second-generation CD20 monoclonal antibodies currently are in development and clinical testing, including a fully human MAb (Teeling et al., 2004) and a humanized form (Stein et al., 2004) in trials in patients with B-cell malignancies (Morschhauser et al., 2005) . Initial results with these compounds suggest that they are well tolerated and can induce responses in various lymphoma subtypes. Whether these agents will be used in settings where single-agent rituximab is less effective (such as chronic lymphocytic leukemia), in late-stage rituximabresistant lymphoma, or early in the disease course instead of rituximab, remains to be determined from clinical trials.
The addition of a radioactive isotope to a MAb offers the addition of targeted radiation to potentially overcome resistance (Goldenberg, 2003; . The radiosensitivity of lymphoma, as well as the availability of accessible target antigens, has led to the development of several radioimmunoconjugates with therapeutic activity (Press et al., 1989; Goldenberg et al., 1991 Goldenberg et al., , 2001 Kaminski et al., 1992; Cheson, 2003 Cheson, , 2005 Press, 2003; Silverman et al., 2004; Theuer et al., 2004; .
In particular, radiolabeled anti-CD20 antibodies have emerged as a new therapeutic modality for the management of NHL. They were evaluated primarily in relapsed indolent lymphoma, whereas other studies have suggested the potential for utility in aggressive NHL subtypes (Cheson, 2005; .
Specifically,
90
Y-and 131 I-labeled anti-CD20 antibodies (ibritumomab tiuxetan (Zevalin), and tositumomab (Bexxar), respectively) have been approved for use in treatment of patients with recurrent indolent lymphoma (Buchsbaum et al., 1992; Wagner et al., 2002; Friedberg and Fisher, 2004; Vose, 2004; Witzig, 2004) . Both therapies combine either the unlabeled chimeric (rituximab) or murine (B1) anti-CD20 antibodies with its radiolabeled murine counterpart. Each of these treatments includes an imaging step followed by a therapeutic step 1 week later. Multicenter evaluation of ibritumomab tiuxetan compared to standard rituximab demonstrated an overall response rate in low-grade, follicular B-cell lymphomas of 80% (30% complete responses (CR)), versus a 56% objective response (16% CR) with rituximab alone . However, there were no significant differences in the duration of response or time to progression. A significant number of subjects can enjoy durable remissions over several years following this form of treatment (Gordon et al., 2004) , and it is clear that the radioactive component of the treatment adds to the efficacy (Davis et al., 2004) . Additional studies have moved radioimmunotherapy into first-line treatment with impressive results, and accumulating evidence suggests that subsequent treatments can be administered as necessary in the majority of patients (Ansell et al., 2002; Kaminski et al., 2005; Dosik et al., 2006) . Single-agent results in more aggressive lymphoma subtypes have been more limited (Zelenetz and Vose, 2002; Fisher et al., 2004; Morschhauser et al., 2004; Cheson, 2005; Coiffier, 2005; , leading to the development of strategies employing sequential combinations of rituximab-CHOP followed by radioimmunotherapy (Morschhauser et al., 2004) . Ongoing studies are evaluating the optimal setting for the incorporation of this important new modality into standard therapies. Additionally, radioimmunoconjugates targeting antigens other than CD20 are under exploration.
CD22 as a target for immunotherapy in B-cell malignancies
The CD22 antigen is a member of the immunoglobulin superfamily and consists of a 135-kDa type I transmembrane sialoglycoprotein (Nitschke, 2005; Tedder et al., 2005) . Its expression is B-cell specific, and is seen during B-cell ontogeny at low levels in the cytoplasm of pro-and pre-B cells, and later on the cell surface on mature cells with IgM and IgD positivity (Do¨rken et al., 1986) . Germinal center B cells weakly express CD22, whereas it is more strongly present in follicular, mantle and marginal-zone B cells. The function of CD22 is not entirely clear, but it appears to be involved in the regulation of B-cell function and survival, CD19 and B-cell antigen receptor (BCR) signal transduction and BCR-induced cell death. Through these roles, it is implicated in the modulation of humoral immunity and in the growth of malignant B cells, suggesting that it may have utility as a target for therapeutic antilymphoma antibodies (Tedder et al., 2005; Steinfeld and Youinou, 2006) .
Seven extracellular Ig domains and a full-length 141 amino-acid cytoplasmic tail comprise the CD22 molecule (Wilson et al., 1991; Engel et al., 1995) , with the Ig regions encoded by exons 4-10 and the transmembrane and cytoplasmic domains encoded by exons 11-15 of the human gene (Law et al., 1993; Wilson et al., 1993) . Several anti-CD22 monoclonal antibodies have been developed, with immunoprecipitation studies demonstrating that they react to different Ig domains. Epratuzumab, a humanized anti-CD22 antibody, which is the subject of this review, and the RFB4 antibody compete for binding to the third Ig domain (Stein et al., 1993) .
Intercellular adhesion appears in part to be mediated by the CD22 molecule, involving a2-6-linked sialic acid residues (Stamenkovic and Seed, 1990; Engel et al., 1993) . Therefore, CD22 is regarded as a member of the sialoadhesin or SigLec subclass of the Ig superfamily, characterized by functioning as lectins (Engel et al., 1993; Kelm et al., 1994) . Additional molecules in this class include other sialic acid-binding receptors, such as sialoadhesin and CD33. Adhesion via CD22 is felt to mediate interactions with other leukocytes, regulate signaling, generate costimulatory effects causing proliferation, or induce apoptotic signals on B-cell function upon exposure to anti-CD22 (Chaouchi et al., 1995; Tuscano et al., 1999; Carnahan et al., 2007) . Immobilized epratuzumab when crosslinked with anti-IgG can induce several effects in assays performed in vitro based on the specific cell type studied. For CD22-positive B-cell lymphoma, immobilized but not soluble epratuzumab can inhibit cellular proliferation, regardless of crosslinking (Nitschke et al., 1997) . CD22 has been observed to negatively regulate signaling (PawlakByczkowska et al., 1989; O'Keefe et al., 1996; Otipoby et al., 1996; Sato et al., 1996) , although other studies with human B-lymphoma cells suggest an involvement of CD22 with the BCR that can inhibit proliferation (Nitschke et al., 1997) . These and other factors appear to be involved in the activity of epratuzumab in the biologically complex groups of lymphoma and autoimmune diseases.
Development and preclinical characterization of epratuzumab LL2, a murine IgG2a MAb (originally named EPB-2), was raised against Raji Burkitt lymphoma cells and demonstrated selectivity for normal and malignant B cells, without binding to Hodgkin's disease, solid tumors or non-lymphoid tissues . Binding was noted to the third Ig-like domain of CD22, and resulted in rapid internalization (10 7 molecules/min) (Carnahan et al., 2003) and phosphorylation of CD22 (Leung et al., 1995) . A humanized IgG 1(k) version of LL2 (called hLL2 or epratuzumab) was generated for potential clinical application (Leonard et al., 2003) . Mechanisms of action appear to differ from those of rituximab, specifically by the ability of epratuzumab to induce CD22 phosphorylation (Leung et al., 1995) , modulate the BCR, as well as to mediate a moderate degree of ADCC, without induction of apoptosis or complement-mediated cell lysis (Leung et al., 1995; Nitschke et al., 1997) . Epratuzumab has also demonstrated clinical activity in NHL, systemic lupus erythematosis (SLE) and Sjo¨gren's syndrome, while providing only moderate B-cell depletion (in contrast to rituximab) (Griffiths et al., 2003; Leonard et al., 2005a, b; Do¨rner et al., 2006; .
The technique of complementarity-determining region grafting was employed (placing the murine parental LL2 antibody hypervariable regions onto a human IgG 1 backbone) in the generation of the epratuzumab construct (Leonard et al., 2003) . Therefore, only the antigen-binding sites (approximately 10% of the antibody) are of murine sequences with the remainder being human. The radiolabeled form, 90 Y-epratuzumab, has also been made through the attachment of the DOTA (1,4,7,10-tetra-azacyclodecane-N,N 0 ,N 00 ,N 000 -tetraacetic acid), used to bind yttrium-90 .
Clinical experience with epratuzumab

Pharmacokinetics
Patients with B-cell malignancies and autoimmune disorders have been treated with epratuzumab in a variety of doses and schedules described in subsequent sections of this review. All of these groups have been evaluated in pharmacokinetic analyses, which demonstrate that antibody levels generally increase with higher administered dose. Most patients have received four weekly intravenous infusions of the agent, with the mean serum half-life (t 1/2 ) increasing from 6.9 to 26.5 days between the first and the fourth infusion (Leonard et al., 2005a, b; Do¨rner et al., 2006) , whereas the C max values also increase likely owing to saturation of antibody binding sites on CD22. Epratuzumab serum levels increase with each infusion and remain detectable in serum 12 weeks later. Whereas extended induction or maintenance schedules have not been studied to date, one would anticipate that therapeutic serum antibody levels could be maintained as with rituximab, and that enhanced therapeutic activity may result (Tables 1 and 2 ).
Clinical trials
The first clinical studies of the LL2 construct were trials evaluating the murine version as a radioimmunoconjugate for tumor imaging (Juweid et al., 1995 (Juweid et al., , 1999 Behr et al., 2002) or as radioimmunotherapy (Siegel et al., 1991; Kreitman et al., 1993; Behr et al., 1999 Behr et al., , 2002 Juweid et al., 1999; Linden et al., 1999 Linden et al., , 2002 Linden et al., , 2005 Vose et al., 2000; Goldenberg, 2001 Goldenberg, , 2003 Postema et al., 2003; Sharkey et al., 2003 Chatal et al., 2005; . Other toxin-conjugate forms have been developed and tested only pre-clinically to date, such as those that include Pseudomonas exotoxin (Newton et al., 2001a, b) and amphibian RNase (Leonard et al., 2005a, b; Newton et al., 2001a, b) .
Following availability of the humanized epratuzumab (Leonard et al., 2003) , over 300 patients with B-cell malignancies have been treated with the unlabeled agent in several clinical trials. In the first of these, a phase I/II open label trial conducted at the Weill Medical College of Cornell University and New York Presbyterian Hospital (Leonard et al., 2005a, b) , 55 patients with recurrent indolent NHL were treated with intravenous epratuzumab weekly for 4 weeks at doses of either 120, 240, 360, 480, 600 or 1000 mg/m 2 . Approximately, half of patients had tumor masses of 5 cm or greater, and half had received four or more previous treatments. Treatment was well tolerated, with toxicity consisting primarily of infusion reactions that were virtually all grade 1 or 2 and no dose-limiting effects were observed. No changes in circulating T cell or immunoglobulin levels were noted, whereas transient B-cell depletion occurred. Objective tumor responses were noted across dose levels, particularly at 360 and 480 mg/m 2 /week. Focusing on FL, the most common indolent NHL subtype, overall 24% of patients had an objective response, including 43% in the 360 mg/m 2 dose group and 27% in the 480 mg/m 2 group. Kaplan-Maier estimate of median duration of objective response was 79.3 weeks, with median time to progression of responders of 86.6 weeks. These observations led to the selection of the 360 mg/m 2 /weekly Â 4 regimen for further study.
In parallel, a similar phase I/II evaluation was performed in 56 patients with recurrent aggressive NHL, predominantly DLBCL (Leonard et al., 2005a, b) . This population was also heavily pretreated. This group also had a median of four prior therapies (25% with prior high-dose chemotherapy and AuSCT), and 84% had bulky disease. Infusions were often completed in 1 h, and toxicities were similar to those observed in the indolent group and were not dose-limiting. Of 35 DLBCL patients treated across all dose levels, 15% showed an objective response and there was no clear evidence of a dose-response. Estimate of median duration of response following four infusions was 26.3 weeks, although notably three of five responders were complete and two were still ongoing at 3 years following treatment.
Based in part on preclinical work suggesting that epratuzumab can enhance anti-tumor effects of anti-CD20 antibodies (Nitschke et al., 1997; Stein et al., 2004) , clinical trials have been conducted to evaluate it in combination with rituximab. The first of these assessed epratuzumab 360 mg/m 2 and rituximab 375 mg/m 2 , each administered weekly for four consecutive weeks in patients with recurrent indolent (n ¼ 16, 15 with follicular) and aggressive (n ¼ 7, all DLBCL) NHL (Strauss et al., 2006) . Toxicity was similar to that observed with rituximab monotherapy, again primarily grade 1 and 2 infusion-related effects. Of follicular NHL subjects, 10 (57%) demonstrated an objective response, including 9/15 (60%) with complete responses. Of six evaluable patients with DLBCL, four (67%) responded, three of which (50%) were complete. Although patient numbers are small, the median time to progression for all indolent NHL patients was 17.8 months, which is approximately double that previously observed with rituximab monotherapy in this histologic group (McLaughlin et al., 1998) .
The safety and encouraging activity of this combination led to two other multicenter studies of epratuzumab in combination with rituximab using the same dosing regimen. In one trial , there was a heterogenous group of 65 patients (34 with follicular, 15 with DLBCL and 16 with other histologies) treated, including 23% with relapsed disease after prior rituximab. Overall, this study demonstrated an objective response rate of 46%, with more responses in follicular NHL (64%, 21/33) and DLBCL (47%, 7/15). Complete response rates were 24 and 33% in these two groups, respectively. Not surprisingly, there was a trend to higher response rates in patients with more favorable prognostic characteristics. Median duration of response was 16 months in follicular NHL and 6 months for DLBCL patients. Tolerability was similar to that observed in the previous pilot trial. These results are consistent with a parallel multicenter, single-arm, trial of this combination in only indolent NHL patients, reported in abstract form (Micallef et al., 2006) . Although these results are intriguing, and the safety data, encouraging, without a concurrently randomized control group treated with rituximab monotherapy it is impossible to determine the possible benefits to the addition of epratuzumab to rituximab in this combination strategy.
To further investigate the interesting activity of epratuzumab monotherapy in DLBCL, a pilot study of epratuzumab and rituximab combined with CHOP chemotherapy in DLBCL patients was recently conducted. Results demonstrated that this approach was well tolerated, and efficacy was promising in this small group of subjects. Overall, 13 of 15 patients (86%) were alive and disease-free at 2 years following therapy (Cesano et al., 2002) . A larger follow-up phase II study is now underway. Additionally, a multicenter trial of epratuzumab in children with acute lymphocytic leukaemia (ALL) is also ongoing, capitalizing on the high expression of CD22 in ALL .
Anti CD22 radioimmunotherapy in NHL
Radioimmunoconjugates of the murine parent form of epratuzumab (mLL2) using either 131 
I or 99m
Tc were initially employed in targeting or imaging studies, with evidence of significant ability to localize sites of B-cell lymphoma (Siegel et al., 1991; Murthy et al., 1992; Stein et al., 1994; Becker et al., 1995; Blend et al., 1995; Gasparini et al., 1995; Juweid et al., 1995; Lamonica et al., 2002; Baum et al., 2004) . Goldenberg and colleagues reported the first clinical studies with the 131 I-labeled murine form of this antibody, demonstrating an overall imaging sensitivity of 82%, including uptake in multiple sites of disease not otherwise detected (Siegel et al., 1991) . Treatment studies were then conducted with seven patients receiving approximately 50 mCi of 131 I-LL2 IgG or F(ab 0 ) 2 resulting in two partial responses. Therapy was well tolerated, with doselimiting toxicity being myelosuppression. Subsequently, the use of 131 I-murine LL2 IgG in a multiple-dosing scheme was reported by Vose et al. (2000) , and objective responses were noted in 7/21 patients. Humanization of the antibody (into epratuzumab) was then performed to minimize immunogenicity and to optimize its pharmacokinetics, safety and efficacy (Leonard et al., 2003) . Studies have suggested that 90 Y-epratuzumab has a higher therapeutic index than that of the 131 I-labeled antibody, presumably relating to the internalization of CD22 upon binding of the radioimmunoconjugate. Relative to 131 iodine, which can be largely extruded from the cell, the 90 yttrium radiometal has a longer intracellular residence time that appears to result in greater tumor radiation dose (Kreitman et al., 1993; Behr et al., 1999 In-labeled epratuzumab (Kreitman et al., 1993) .
Since 90 Y-epratuzumab is the first humanized radioimmunoconjugate under clinical application, multiple or fractionated dose regimens are feasible due to the diminished risk of an immune response to the antibody (in contrast to murine agents). Efforts have been made to evaluate repeated doses, once weekly over 2 or 3 weeks, in both single-or multi-center studies. In one study of low dose of (5 mCi) 90 Y-epratuzumab given to 16 heavily pre-treated NHL patients for 2-4 infusions, no significant infusional reactions were observed though, as expected, dose-limiting toxicity was myelosuppression (Postema et al., 2003) . The overall objective response was 62% in both indolent (75%) and aggressive disease (50%), with complete responses in 25% of patients, which were durable (event-free survival, 14-41 months). In another ongoing fractionated dose trial, investigators to date have employed doses of up to 37.5 mCi/m 2 (3 Â 12.5 mCi/m 2 given weekly) with acceptable toxicity (136 and personal communication, . These radiation doses are more than twice those employed with 90 Y ibritumomab tiuxetan in its standard administration regimen. In the initial 21 patients from this ongoing study (Chatal et al., 2005) , 13 (62%) had an objective response, including patients with indolent and aggressive disease (7/10 (70%) and 6/11 (55%), respectively), across different histologies (follicular NHL, 7/10 (70%); DLBCL, 3/4 (75%); mantle cell, 3/7 (43%)), and in patients with prior rituximab (10/19, 53%). Most objective responses were complete (11/13) and in some cases have been durable for over 1 year. The optimization of this multidose radioimmunotherapy approach is currently continuing.
Epratuzumab in autoimmune disorders
The importance of CD22 in the regulation of B-cell proliferation and function led to the evaluation of epratuzumab as a therapy for autoimmune disorders, including a phase II study of patients with SLE. Subjects received epratuzumab at a dose of 360 mg/m 2 every other week for a total of four doses (Do¨rner et al., 2006) and demonstrated improvement in all 14 patients treated with four doses of epratuzumab as measured by the British Isles Lupus Assessment Group categorization of SLE activity levels. Treatment was again well tolerated, and was administered over approximately 30 min on average. Epratuzumab was detectable in the serum for as long as 18 weeks in most patients, whereas partial depletion of B cells for up to 6 months. This work has led to two ongoing, placebo-controlled phase III trials of epratuzumab in specific categories of SLE patients that will help to define the role of the agent in this setting.
Another area of autoimmune disease where epratuzumab may have a potential role is in primary Sjo¨gren's syndrome. In a trial of 15 such patients receiving the same dose as in the SLE study, over half of patients had improvement in disease parameters that gradually occurred up to 6 months after therapy . Partial depletion of circulating B cells was also demonstrated, lasting for several months.
One potential advantage of a humanized antibody is a lower risk (compared to a murine agent) of antiantibody formation. This is particularly important in autoimmune disease, where patients may have more intact or overactive immunity, as opposed to the immunosuppressed state (due to disease and treatment) that exists in most lymphoma patients. Serum human anti-human antibody titers were determined and in NHL and Sjo¨gren's syndrome studies, only 2.4% of the patients had positive enzyme-linked immunosorbent assay results, all borderline positives or low-level values, without clinical sequelae . No evidence of immunogenicity was reported in the SLE study (Do¨rner et al., 2006) .
Conclusions
As the second unlabeled MAb (following rituximab) to undergo extensive evaluation in B-cell lymphoma, the clinical development of epratuzumab to date in NHL illustrates the opportunities and challenges of developing novel biologic antibodies in this era. Studies have demonstrated that this humanized anti-CD22 MAb has excellent tolerability either alone or in combination with rituximab, and has significant single-agent activity in FL and in DLBCL, the two most common NHL subtypes. As the therapy of relapsed indolent lymphoma is largely centered around rituximab, a key issue is whether the addition of epratuzumab to rituximab in a combination antibody strategy can augment the activity of the single-agent. Phase II studies of this combination demonstrated a suggestion of enhanced effects; however, the lack of a concurrent control group treated with rituximab alone makes interpretation a challenge due to the fact that historical data were derived from patients that differ significantly in prior therapy. Although efficacy data with epratuzumab þ rituximab in indolent lymphoma are not definitively different than those seen historically with rituximab alone (though complete response rates appear higher than expected), they compare favorably with recent studies of other rituximab combinations with agents such as interleukin 2, Bcl-2 antisense, CpG oligonucleotides and the anti-CD80 antibody, galiximab . One interpretation is that the widespread use of rituximab alone or in combination with chemotherapy early in the course of treatment of FL has resulted in lesser sensitivity to rituximab (alone or in combination with other biologics). It is now evident that the presence of a control group treated with rituximab alone (in a randomized phase II or III trial) is necessary to draw definitive conclusions on the merits of a combination regimen.
Perhaps the most intriguing findings with epratuzumab are results in aggressive lymphoma, where durable single agent responses have been seen in patients with recurrent disease, and where the combination with rituximab (with or without CHOP chemotherapy) appears promising. The reasons for these findings, as well as those seen in autoimmune disease, seem less likely to be due to ADCC and potentially relate to signaling effects on malignant or normal B cells, respectively. One can envision a day when lymphoma patients may be treated with a cocktail of biologic agents working in a targeted fashion, with less toxicity. Clearly, the main issue in the development of these strategies remains the challenge in defining the optimal setting for the use of epratuzumab among the array of active treatment options to maximize potential benefits to patients. We anticipate that expanded, multicenter randomized trials, some of which are ongoing, will better clarify the picture.
